<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>24157323</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Ruiz, M</dc:author>
<dc:author>Irigoyen, C</dc:author>
<dc:author>Macías-Murelaga, B</dc:author>
<dc:author>Bascarán, L</dc:author>
<dc:author>Gibelalde, A</dc:author>
<dc:author>Aldazabal, M</dc:author>
<dc:description xml:lang="en">METHOD Prospective observational study including 10 patients (age range: 27-74 years) with recurrent retinal detachment (RD) and proliferative vitreoretinopathy (PVR) and 2.8 mean unsatisfactory previous surgeries. Densiron® was injected in all patients, with surgical retinectomy being required in 70% of them. Minimum follow-up time was 12 months. RESULTS The mean length of time before Densiron® withdrawal was 4 months. Three patients (30%) presented with a new RD. The main complication detected was cataract development. No relationship was found between re-detachments and tamponade time, baseline disease or RD evolution time. Densiron® may be a good option in cases of recurrent RD in which previous treatment with scleral buckle, gas and/or 1,000/5,000 silicone oils has proven to be unsatisfactory.</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:subject>Retinal detachment</dc:subject>
<dc:subject>Aceite de silicona pesado</dc:subject>
<dc:subject>Tamponador</dc:subject>
<dc:subject>Densiron 68</dc:subject>
<dc:subject>Desprendimiento de retina</dc:subject>
<dc:subject>Heavy silicone oil</dc:subject>
<dc:subject>Proliferaciones vitreorretinianas</dc:subject>
<dc:subject>Proliferative vitreoretinopathy</dc:subject>
<dc:subject>Tamponade</dc:subject>
<dc:date>2013 Nov </dc:date>
<dc:title xml:lang="es">Aceite de silicona pesado (Densiron(®) 68) en vitreorretinopatía proliferativa: 4 años de experiencia.</dc:title>
<dc:title xml:lang="en">[Heavy silicone oil (Densiron® 68) in proliferative vitreoretinopathy: 4 years of experience].</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
